The causative role of coronarv artery thrombosis in acute transmural myocardial infarction is
well estab-lished [1, 2]. Rupture of atheromatous plaque leads to occlusive thrombosis …

In the past decade, thrombolytic therapy has become standard treatment of acute myocardial
infarction. When the importance of thrombosis in the pathogenesis of acute infarction was …

Trials during the 1980s established that thrombolytic therapy restores coronary blood flow
rapidly and reduces mortality compared to control or placebo therapy in acute myocardial …

Thrombolytic therapy remains a mainstay for the treatment of patients with acute myocardial
infarction. This therapy has been the subject of intense investigation and multiple studies as …

The DECADE of the eighties is character-ized by major advances in the management of
patients with evolving myocardial infarction. Large-scale, placebo-controlled studies have …

The rationale for thrombolytic treatment of acute myocardial infarction is based on two
established facts and a reasonable assumption. The first fact is that a thrombus obstructing …

Thrombolytic agents are plasminogen activators that convert plasmin ogen, the inactive
proenzyme of the fibrinolytic system in blood, to the proteolytic enzyme plasmin. Plasmin in …

Substantial advances have been made in the application of intravenous thrombolytic agents
for acute myocardial infarction since their introduction 10 years ago. Dosage regimens and …

OBJECTIVE: To review the literature on the use of thrombolytic agents in the
pharmacotherapeutic management of acute myocardial infarction (AMI). DATA SOURCE …

The reduction in morbidity and mortality associated with thrombolytic therapy in patients with
acute myocardial infarction was initially attributed to early restoration of arterial patency …